CKD Corporation

Equities

6407

JP3346800000

Industrial Machinery & Equipment

Market Closed - Japan Exchange 02:00:00 2024-06-14 am EDT 5-day change 1st Jan Change
3,305 JPY +0.76% Intraday chart for CKD Corporation +5.59% +30.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tan Chong International and Subaru Corporation Initiate Phasing Out Complete Knock Down Business Model MT
Tan Chong International to Shift from CKD Business Model to CBU Sales Model from Japan MT
Jefferies Adjusts CKD'S Price Target to 3,700 Yen From 4,000 Yen, Keeps at Buy MT
AstraZeneca: expects a sharp rise in kidney disease CF
TVS Supply Chain's Supply of CKD Kits to TVS Motor Crosses 500,000 MT
Jefferies Upgrades CKD to Buy From Hold, Adjusts Price Target to 4,000 Yen From 2,600 Yen MT
Novo Nordisk: EU could authorize Wegovy by April CF
Novo Nordisk: EU authorization for Wegovy by April? CF
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia MT
Jefferies Downgrades CKD to Hold From Buy, Adjusts Price Target to 2,600 Yen From 2,300 Yen MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD MT
FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia MT
FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia MT
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease MT
Hansoh Pharma's Three Drugs Added to China’s National Reimbursement Drug List MT
AstraZeneca Discontinues Two Phase 3 Evidence Trials of Lokelma in Managing Hyperkalemia MT
AstraZeneca: discontinuation of two phase III trials for Lokelma CF
Miners give FTSE 100 boost thanks to China PMI AN
AstraZeneca discontinues two phase III evidence trials for Lokelma AN
AstraZeneca Ends Two Late-stage Studies of Hyperkalemia Drug Lokelma on Delayed Schedules MT
Stocks called higher; UK house prices fall annually AN
AstraZeneca to scrap two trials on drug that curbs potassium RE
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast MT
Foyou Pharma Gets Nod to Market Roxadustat API MT
Jefferies Adjusts CKD’s Price Target to 2,300 Yen From 2,400 Yen, Keeps at Buy MT
Chart CKD Corporation
More charts
CKD Corporation is engaged in the manufacture and sale of automatic machinery and equipment. The Automatic Machinery segment offers automatic packaging systems, image processing inspection systems, lithium-ion battery manufacturing systems, three-dimensional solder printing inspection machines, lighting manufacturing systems and capacitor manufacturing systems. The Machinery segment offers index units, direct drive motors, pick-and-place units, pneumatic directional control valves, manual switching valves, pneumatic cylinders, cylinders with valve, special cylinders, electric actuators, cylinders with multi-function, filters, regulators, lubricators, fittings, speed controllers, refrigeration type dryers, dry type dryers, membrane type dryers, mainline filters, flow sensors, pressure sensors and various valves. The Company also involves in the insurance agency and factoring businesses.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3,305 JPY
Average target price
3,657 JPY
Spread / Average Target
+10.64%
Consensus
  1. Stock Market
  2. Equities
  3. 6407 Stock
  4. News CKD Corporation
  5. Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD